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ABSTRACT
We defined the stem cell profile of K562 line, demonstrating the expression of 
the Embryonic Transcription Factors Oct3/4, Sox2, Klf4 and Nanog. This profile was 
associated with a high vulnerability to the physiological oxidizable substrate pyruvate. 
remarkably, this substrate was shown to be innocuous, even at the highest doses, 
to normal differentiated cells. This vulnerability is based on a complex metabolic 
trim centered on the cellular redox state expressed by the NADP/NADPH ratio 
geared by the mitochondrial respiratory chain. Flow cytometry revealed that the 
inhibition of this chain by antimycin A produced cell accumulation in the S phase of 
cell cycle and apoptosis. This block negatively interferes with the aerobic synthesis of 
purines, without affecting the anaerobic synthesis of pyrimidines. This imbalance was 
reproduced by using two antifolate agents, LY309887 and raltitrexed (TDX), inhibitors 
of purine or pyrimidine synthesis, respectively. All this revealed the apparent paradox 
that low doses of TDX stimulated, instead of inhibiting, leukemia cell growth. This 
paradox might have significant impact on therapy with regard to the effects of TDX 
during the intervals of administration, when the drug concentrations become so low 
as to promote maintenance of dormant cancer cells in hypoxic tissue niches.
INTRODUCTION
Modern cancer chemotherapy include agents which 
interfere with intricate fundamental metabolic networks 
[1, 2]. The fact that these networks are often not thoroughly 
defined may make it difficult to predict the effects of a 
therapeutic strategy. A further difficulty derives from the 
necessity of exploring the effects of therapeutic agents 
in hypoxia, because cancer stem cells have a tendency to 
adapt to, and survive in, these environmental conditions 
[3, 4], implying high resistance to radio- and chemo-
therapy [5]. Recently, crucial information in this field has 
been obtained with the identification of embryonic stem 
cells (ESC) [6] within the bulk of highly anaplastic tumors 
of any hystogenesis whatever [3, 4]. These cells can be 
identified from their expression of embryonic transcription 
factors (ETF), whose physiological role is the silencing 
of differentiation genes, and thus the maintenance of the 
undifferentiated embryonic state [7–11]. ESC originate at 
the gastrula stage under hypoxic conditions and migrate 
into adult tissues, becoming the adult stem cells after 
drastically reducing their self-renewal and plasticity. The 
ectopic finding of ESC in an adult tissue is now regarded as 
a potential warning that a cancer is about to begin or return, 
while the presence of ESC within a tumour is a crucial sign 
of severe anaplasia [12–14].
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Metabolic studies [3, 4, 15] carried out in our 
laboratory employing the highly anaplastic Yoshida’s 
ascites hepatoma AH130 cells revealed the basis of 
cancer adaptation to hypoxia. We demonstrated that the 
very same metabolic features responsible for this process 
are accompanied by the susceptibility to a powerful 
cytotoxic effect exploited by physiological factors, 
such as pyruvate, tetrahydrofolate (FH4) and glutamine. 
This paradox is also found in human anaplastic tumors 
with a totally different histogenesis, and reflects a 
complex metabolic interference of these agents with 
purine metabolism. This interference culminates in 
the impairment of the amplification of the purine base 
pools which is required to fulfil the G1/S transition of 
cell cycle. Such an impairment implies an inadequate 
mitochondrial apparatus, like that characterizing the 
hypoxia-adapted cells surviving in the dormant state 
by means of a glycolysis-oriented metabolism [15, 
16]. This trim was first discovered by Warburg in 1923 
in cancer cells, describing the aerobic glycolysis: this 
metabolic pathway consists of the arrest of aerobic 
utilization of glucose at the level of pyruvate, which is 
mostly exported upon reduction to lactate [15, 17, 18]. 
This is a tremendous waste of the energy which could be 
produced by the aerobic degradation of glucose to H2O 
and CO2 through the Krebs cycle and the mitochondrial 
respiratory chain. We demonstrated that in this metabolic 
configuration the addition of an excess of pyruvate will 
lead to the saturation of respiratory chain at the expense 
of the re-oxidation of crucial cytosolic dehydrogenation 
steps geared by the NADP/NADPH ratio [3, 4]. Indeed, 
the reducing equivalent (H+ or electrons) derived from 
these dehydrogenations cannot be disposed of through 
the metabolic shuttles [19] leading to the respiratory 
chain (see Scheme 1). This sequence will inhibit the 
growth of any type of anaplastic cancer, through a 
ten-fold reduction of the cellular NADP/NADPH 
ratio, that is, at the same level in anaerobiosis as in the 
presence of antimycin A, a powerful specific inhibitor 
of the respiratory chain [4, 15]. The pyruvate inhibition 
is removed by the addition of preformed purine bases 
(adenine or guanine) as well as by folate (F), indicating 
that its mechanism is mediated by the impairment of the 
NADP-dependent dehydrogenation of methylen-FH4 
(CH2-FH4) to methenyl-FH4 (CH-FH4), catalyzed by the 
CH2-FH4-dehydrogenase [3, 4, 19].
Scheme 1: Role of the cellular redox state in the control of purine synthesis. The core of this metabolic network is the 
cell redoxstate expressed by the cytosolic NADP/NADPH ratio. This ratio regulates the transfer of reducing equivalents (H+) from the 
methylen-tetrahydro-folate (CH2-FH4) to methenyl-tetrahydro-folate (CH-FH4). This NADP-dependent reaction (generating NADPH) is a 
limiting step of the synthesis of purine ring required for the amplification of purine pools indispensable for G1-S transition. A fundamental 
role in the regulation of NADP/NADPH ratio is played by folate, whose anaerobic reduction to FH4 by dehydrofolate-reductase (DHFR) 
generates NADP, compensating the anaerobic restriction of this factor. Whatever the mechanism increasing cytosolic NADPH, including 
pyruvate, glutamine through the glutaminolytic pathway, or the inhibition of DHFR by an excess of FH4, the cytosolic NADPH increase 
has an inhibitory effect on cell recruitment into S, unless it is removed by the shuttle mechanisms, which discharge the cytosolic reducing 
equivalents onto the mitochondrial respiratory chain. This role of the shuttles accounts for the fact that the activity of the chain is crucial 
for the G1/S transition, which is impaired by a specific inhibitor like antimycin A or by anaerobiosis. A similar inhibition can be brought 
about out in air whenever the chain, although not inhibited, is saturated by reducing equivalents produced by oxidizable substrates of the 
Krebs cycle, mostly pyruvate. This inhibitory effect of pyruvate accounts for the crucial role of its disposal of by the reduction to lactate, 
and the consequent exportation into the environment, in hypoxia-adapted cancer cells in air (the aerobic glycolysis, traditionally named the 
Warburg’s effect).
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In the present study, we tested the antitumor activity 
of pyruvate on Chronic Myeloid Leukemia (CML) cells 
of the K562 stabilized line [20]. A high percentage of 
these cells expresses ETF and exhibited a high sensitivity 
to pyruvate. Thus, K562 cells turned out to be suitable 
for establishing whether and how much CML is subjected 
to the same metabolic network previously described 
in Yoshida’s hepatoma cells [3, 4]. We answered to 
these questions positively, taking advantage of two 
antifolate selective inhibitors of the synthesis of purine 
or pyrimidine DNA precursors, such as LY309887 
[21, 22] and raltitrexed (TDX) [22], respectively. These 
compounds display potent activity against human 
leukemia cells [23–26], and may turn out to be effective 
agents for the clinical treatment of leukemia [27]. 
LY309887 is a folate analogue that selectively inhibits 
glycinamide-ribonucleotide-formyl-transferase (GARFT) 
[28], while TDX selectively targets thymidylate-synthase 
(TS) [29]. Our experiments revealed that the reductive 
shift of the hypoxic NADP/NADPH ratio determines the 
imbalance of the purine/pyrimidine ratio, altering the 
correct base assembly into DNA by DNA-polymerase. 
These results made it possible to observe and explain 
the apparent paradox that, in hypoxic conditions, low 
concentrations of TDX stimulate, instead of inhibiting, 
K562 cell growth.
RESULTS
The pluripotent stem cell profile of the K562 cell 
line: ETF expression
Fig. 1 shows that up to 60–70% of the K562 cell 
population expresses four fundamental ETF, such as 
Oct3/4, Sox2, Klf4 and Nanog. These ETF are so crucial 
for the maintenance of the ESC undifferentiated phenotype 
that their transfection is sufficient to reprogram adult 
differentiated cells, of any histogenesis whatever, down to 
the pluripotent state [8, 9]. We previously found that ETF 
expression in tumors is associated with vulnerability to 
pyruvate, a phenomenon which represents the hallmark of 
the adaptation of ESC to hypoxia, and that the detrimental 
effect of pyruvate on cell number in culture increases in 
proportion to the level of tumor anaplasia, being maximal 
for AH130 cells [3, 4]. The underlying metabolic scenario 
was deepened as described hereunder.
Figure 1: Expression of ETF in K562 cells. ETF (Oct3/4, Sox2, Klf4, Nanog) expression in K562 cells. Bar: 50 μm; magnification: 
60x. Cell nuclei were stained with Hoechst 33258.
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K562 cell growth inhibition by pyruvate or in 
hypoxia and the effects of folate addition
Fig. 2A shows that pyruvate concentration-
dependently reduced K562 cell number in day-7 cultures 
incubated in air. Thus, K562 cells seem sensitive to 
pyruvate similarly to AH130 cells. This similarity allows 
allows to evaluate K562 cells with respect to the metabolic 
analysis performed on AH130 cells. As summarized in 
the Introduction, the pyruvate inhibition of cell growth 
is removed by the addition of purine bases or folate to 
cultures. On this basis, we determined the effects of folate 
on the growth kinetics of K562 cells incubated in air or 
severe hypoxia (0.1% O2 in the incubation atmosphere). In 
air, the cell population grew up to 9 × 105 cells/ml at day 7 
and declined thereafter to reach a steady-state at about 
4–5 × 105 cells/ml at days 14–21 (Fig. 2B). This decline 
is due to cell crowding, with the consequent nutrient 
shortage in the absence of medium renewal. When cultures 
were incubated in hypoxia, cell growth was abolished 
[30–34]. Fig. 2C shows that, at day 21 of incubation in 
hypoxia but not in air, folate addition markedly increased 
the total cell number in comparison to the value obtained 
for the respective untreated control. It is worth noting 
that relatively low concentrations of folate determined a 
maximal increase of cell number in hypoxia-incubated 
cultures.
Effects of antimycin A on the cytosolic NADP/
NADPH ratio in K562 cells
Fig. 3 shows that the treatment with antimycin A 
(6 × 10−6M), an inhibitor of complex III of mitochondrial 
respiratory chain, of cultures incubated in air for 4 days 
produced a drastic reductive shift (Fig. 3A), resulting in 
a marked decrease of the NADP/NADPH ratio (Fig. 3B). 
Figure 2: The sensitivity to pyruvate of K562 cells in comparison with AH130 cells. Hypoxic inhibition of K562 cell growth 
and its removal by folate addition . A. concentration-dependence of the detrimental effect of pyruvate on viable cell number in culture. 
Data are expressed as percent variation with respect to control values at day 7 of incubation in air. Triangles: AH130 cells; circles: K562 cells. 
B. Cells were incubated in air (open circles) or hypoxia (0.1% O2; solid circles) for the indicated times. Values (total number of viable cells) 
are means ± S.E.M. of three independent experiments. C. Cells were incubated for 21 days in air (open circles) or hypoxia (solid circles) in the 
presence of different folate concentrations. Data are expressed as percent variation (∆%) with respect to the control value (day-21 cultures).
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We had previously shown that this shift is abolished by 
folate addition [4] through the reaction F + NADPH → 
FH4 + NADP. Provided folate is abundant, this anaerobic 
reaction supplies the NADP necessary for the activity 
of cytosolic dehydrogenases, including CH2-FH4-
dehydrogenase, which allows purine synthesis in hypoxia 
[4] (see Scheme 1). Altogether, these data suggested that 
K562 cell recruitment into the cycling state is geared by 
the NADP/NADPH ratio as a function of respiratory chain 
activity or folate supply.
Effects of antimycin A on total number and cell 
cycle distribution of K562 cells
Fig. 4A shows that cell growth occurring in air was 
markedly inhibited following antimycin A addition. This 
inhibition was apparently independent of the stabilization 
of Hypoxia-Inducible Factor (HIF), which is driven via the 
activation of specific sensors of low oxygen tension [35]. 
The effects of antimycin A on cell cycle, as determined by 
flow cytometry, are shown in Fig. 4B–4F. In control cultures, 
when cell population attains the steady state (C, D), cell 
percentage progressively increases in the G1 phase of cell 
cycle and decreases in S, undergoing evident apoptosis at 
day 7 (D). In antimycin A-treated cultures, a marked cell 
accumulation in S was already evident at day 4 (E), followed 
by a further increase and massive apoptosis at day 7 (F). 
Thus, the antimycin A block of respiratory chain interfered 
with cell transition through cell cycle. These data are very 
similar to those reported by Hastak [36], showing that the 
imbalance of pyrimidine pools by N-(phosphonacetyl)- 
L-aspartate (PALA) produces base misincorporation into 
DNA during the first S phase, which is sufficient to bring 
about cell death during the second cell cycle.
Effects of purine synthesis inhibition and 
adenine on the total number and cell cycle 
distribution of K562 cells
LY309887, a specific inhibitor of purine synthesis, 
markedly reduced the total number of cells at day 7 of 
incubation in air (Fig. 5A), well in keeping with the 
effects of antimycin A shown above. Such a reduction was 
abolished by the addition of adenine to LY309887-treated 
cultures. These effects are also evident from Fig. 5B–5E, 
which shows that the cell cycle distribution changes 
induced by the inhibitor at day 4 (D vs C) were abolished 
in the presence of adenine (E). This effect implies that the 
endogenous pyrimidine pool is per se able to sustain K562 
cell growth, once the insufficient endogenous purine pool 
is amplified by the addition of adenine.
Effects of antimycin A on the A/T and G/C ratios
The above data must be interpreted in the light 
of the available information about the close association 
between DNA synthesis and turnover and the balance of 
various deoxy-nucleotide-triphosphate (dNTP) pools [36]. 
It is because of this close association that any imbalance 
between purines and pyrimidines will produce a high ratio 
of base misincorporation of these precursors into DNA, 
generating mutations. Up to a certain limit, these mutations 
can be repaired by an efficient p53, whereas they induce 
cell apoptosis when the DNA “house keeper” is deleted. 
We found that p53 is totally deleted in K562 as well as 
AH130 cells [3], implying that in these cells any serious 
alteration of the purine/pyrimidine ratio, such as that 
caused by a restricted purine synthesis or the impairment 
of respiratory chain by pyruvate or antimycin A [3, 4, 15], 
Figure 3: Effects of antimycin A on NADP and NADPH levels and their ratio in K562 cells. Cells were incubated for 4 days 
in air in the presence or the absence of 6 × 10−6M antimycin A and metabolite concentrations measured by HPLC technique. A. values, 
expressed as nmol ×106 cells, are means ± S.E.M. of data obtained in triplicate. B. NADP/NADPH ratios from data reported in panel A.
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Figure 4: Effects of antimycin A on K562 cell growth and cell cycle distribution. A. Cells were incubated for the indicated 
times in air (open circles) or in the presence of 6 × 10−6M antimycin A (solid circles). Values (total number of viable cells) are means of 
± S.E.M. of data from three independent experiments. B–F. Cell cycle distribution, measured by flow cytometry, in air (control) versus 
antimycin A (ant.A) at the indicated incubation times.
Figure 5: Effects of inhibition of purine synthesis and its removal by adenine. K562 cells were incubated in air for 7 days (A) or 
for the indicated times (B–E) in the absence (control) or the presence of 10−9M LY309887 (LY) or LY plus 0.1 mM adenine (LY+ad). A. values 
represent the total number of viable cells at day 7 of incubation and are means ± S.E.M. of three independent experiments. B–E. cell cycle 
distribution at the indicated incubation times in cultures incubated in the absence (control) or the presence of LY309887 or LY309887 + adenine.
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will promote lethal apoptosis. Consistently, as shown in 
Fig. 6A, antimycin A brought about a 14-fold decrease 
of the adenine/thymine ratio (A/T) in AH130 cells, 
whereas it only halved the guanine/cytosine ratio (G/C). 
This indicates that antimycin A determined a major effect 
on the purine pool (adenine and guanine), with a minor 
effect on the pyrimidine pool (thymine and cytosine). This 
conclusion was confirmed by the experiments reported 
in Fig. 6B, which shows the concentration/response 
relationship of the artificial amplification (at time 0 of 
incubation) of the purine or pyrimidine pools to K562 cell 
number (at day 7) in the presence of antimycin A. Purines 
determined an increase of cell number by up to almost 
60%, while pyrimidines produced only negative effects. 
Purine addition determined an increase up to 0.25 mM 
and a marked decline at higher concentrations. Pyrimidine 
addition determined a decrease of K562 cell number over 
the whole range of concentrations (0–0.30 mM).
These results led us to draw the following 
inferences: a) the purine pools are made deficient by 
the block of respiratory chain (antimycin A), accounting 
for the reduction of cell number in culture with respect 
to control; this reduction is reverted by base addition; 
beyond a well-defined limit, the increase of purine pools 
becomes detrimental, despite a good adenine/guanine 
balance; this limit is evidently attained when the ratio 
purine/pyrimidine is optimal; b) the pyrimidine pools are 
optimal, or at least sufficient, for maximal growth in the 
presence of antimycin A, so that their further amplification 
is only detrimental, even at minimal concentrations. Thus, 
in summary, the optimal growth conditions for K562 cells 
in air are guaranteed by a well-defined purine/pyrimidine 
ratio; this equilibrium is altered by hypoxia, where the 
oxygen-dependent purine synthesis is depressed, leaving 
the pyrimidine pools unaltered.
Effects of purine or pyrimidine synthesis 
inhibition in air in the absence or the 
presence of antimycin A
The above data and inferences suggested to us to 
compare the effects of specific inhibitors of purine or 
pyrimidine synthesis, such as LY309887 or raltitrexed 
(TDX), respectively, on the recruitment of K562 cells to 
growth. Fig. 7A shows the concentration/response effects 
of LY309887 or TDX on the total number of viable K562 
cells in cultures incubated in air for 7 days. LY309887 
started to inhibit cell growth at 10−9 M, reaching the 
maximal effect around 5 × 10−8M; this indicates an 
extreme sensitivity of purine pools to this inhibitor. On 
the other hand, the inhibition brought about by TDX 
started only at 5 × 10−8 M, to reach the maximum at almost 
10−7M, indicating that K562 cells are at least ten times 
more sensitive to the restriction of purines than to that 
of pyrimidines. In other words, the endogenous purine 
pool of these cells in air is insufficient to bring about cell 
cycling upon exposure to even minimal concentrations 
of LY309887. By contrast, the pyrimidine pool remains 
sufficient for the maximal growth in the presence of 
relatively high concentrations of TDX.
The crucial role played by the balance of DNA 
base pools emerged from the experiments reported in 
Fig. 7B–7D, where the concentration/response effects 
of TDX on viable cell number in the absence or the 
presence of antimycin A were compared. Fig. 7B, 7C 
shows the effects of TDX on the time-course of K562 
Figure 6: Effects of antimycin A on the A/T and G/C ratios in AH130 cells and of purine or pyrimidine addition on 
K562 cell number. A. AH130 cells were incubated for 18 h in air in the absence (control) or the presence of 6 × 10−6M antimycin A 
(ant.A) and base concentrations determined by HPLC technique; A/T = adenine/thymine, G/C = guanine/cytosine ratios. B. K562 cells were 
incubated for 7 days in the presence of 6 × 10−6M antimycin A and in the absence or the presence (from time zero) of different concentrations 
of purines (A + G) or pyrimidines (C + T + U) at the 1:1 ratio. Values represent the total number of viable cells at day 7 of incubation and 
are expressed as percent variation (∆%) with respect to the value obtained for the base-untreated control (antimycin A alone).
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cell number in cultures incubated in air in the absence (B) 
or the presence (C) of antimycin A. TDX concentration-
dependently inhibited cell growth in air, whereas, in the 
presence of antimycin A, TDX produced an unexpected 
stimulation of cell growth in the range 10−8 to 5 × 10−8M. 
This counterintuitive result indicates that a modest 
inhibition of pyrimidine pool by low concentrations of 
TDX stimulated cell growth by attenuating the marked 
disequilibrium between the purine and pyrimidine pools. 
This phenomenon is even more clearly shown in Fig. 7D, 
where the data relative to the effects of TDX on viable cell 
number at day 7 of incubation are reported as percentages 
of the relative control (TDX-untreated, incubated in the 
presence or the absence of antimycin A). Such a paradox 
makes it predictable that TDX could have a detrimental 
impact on therapy, promoting the growth resumption of 
dormant cancer stem cells hidden in hypoxic niches [37] 
(see Discussion).
DISCUSSON
The results of this study led us to conclude that K562 
cells are a CML cell population endowed with an epigenetic 
and metabolic trim that parallels the neoplastic progression 
of a number of malignant tumors of different histogenesis. 
This trim characterizes the tumor converging phenotype 
[15], whose essential feature is an extreme morphological 
and metabolic simplification centered on a high nucleus/
cytoplasma ratio and a poor, easily-saturated, mitochondrial 
apparatus. This feature, which may well be responsible for 
cancer radio- and chemio-resistance, resembles the one we 
described for ESC expressing ETF [38, 39], whose energetic 
metabolism, based on aerobic glycolysis, is vulnerable to 
pyruvate, as outlined in the Introduction. We showed that 
this metabolic configuration predisposes to unbalance the 
purine/pyrimidine ratio, leading to cell cycle arrest and 
apoptosis [36], a tendency that is realized in hypoxia.
Figure 7: Effects of the inhibition of purine or pyrimidine synthesis in air in the presence or the absence of antimycin 
A on the time-course of K562 cell number in culture. The raltitrexed paradox. A. Cells were incubated in air in the absence or 
the presence of the indicated concentrations of raltitrexed (TDX; squares) or LY309887 (circles) and the number of viable cells in culture 
counted at day 7 of incubation. Data are expressed as % of values obtained for the drug-free control. B, C. Cultures were incubated in air in 
the absence (air) or the presence (ant.A) of antimycin A and in the absence (control) or the presence of the indicated concentrations of TDX, 
added at time 0; the total number of viable cells in culture was counted at the indicated times of incubation. Values are means ± S.E.M. of 
three independent experiments. D. Cells were incubated in air in the absence (air; triangles) or the presence (ant.A; squares) of antimycin A 
and in the presence of the indicated concentrations of TDX; the total number of viable cells in culture was counted at day 7 of incubation. 
Data (derived from panels B and C) are expressed as ∆% of TDX-free control.
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Scheme 2 shows the biochemical pathways 
implicated in DNA base synthesis [40], which share 
CH2-FH4 as the initial metabolite and set in motion no less 
than three syntheses, those of: (1) purines; (2) pyrimidines; 
(3) methionine and acetylCoA derivatives of methyl-FH4 
(CH3-FH4). Pathway (3) leads to the anaerobic synthesis of 
CH3-FH4 through the reduction of CH2-FH4 by the NADPH-
dependent CH2-FH4-reductase, producing NADP. Pathway 
(2) consists of the anaerobic conversion of dUMP to dTMP 
catalysed by thymidylate-synthase (TS), in which CH2FH4 
acts as a co-substrate, one-carbon unit donor. Pathway (1) 
generates the purine pools through the RedOx pathway,  
so-called to indicate its dependence on the NADP/NADPH 
conversion [40]: this pathway, in fact, requires NADP at 
two crucial steps: a) the oxidation of CH2-FH4 to CH-FH4 
catalyzed by the CH2-FH4-dehydrogenase; b) the conversion 
of CH-FH4 to formyl-FH4 (10-HCO-FH4) catalyzed by 
the CH-FH4-cyclohydrolase. Both a) and b) reactions are 
strictly NADP-dependent, requiring a high NADP/NADPH 
ratio, so that they are inhibited when the respiratory chain 
is blocked by antimycin A or saturated by pyruvate. This 
inhibition can be removed by the addition of folate through 
the reaction F + NADPH → FH4 + NADP catalyzed 
by the dihydrofolate-reductase (DHFR). Thus, it seems 
straightforward to assume that hypoxia or antimycin A block 
purine synthesis, while they favour pyrimidine synthesis 
via the maintenance of CH2FH4 levels. On this assumption, 
one would expect either treatment to generate an imbalance 
between the two types of bases, altering the DNA synthesis 
operated by DNA-polymerase, which requires a strict 
equilibration of their ratio. More important still, we were 
able to show that, in the absence of this equilibrium, a 
high level of misincorporations occurs, likely to generate 
mutation and hence apoptotic cell death [36, 41].
With regard to cancer chemotherapy, the biochemical 
network summarized in Scheme 2 needs to be better 
characterized. In this respect, the K562 cell line emerged 
as a suitable model to study the response of blast-crisis 
CML cells to “antifolate” drugs such as LY309887 or TDX. 
This biochemical network, on the other hand, is of general 
relevance to determine the role of cells expressing ETF in 
the onset and development of cancer. In this respect, it is 
worth pointing out that ESC are physiologically generated 
in the gastrula, an early embryo stage characterized by 
Scheme 2: The metabolic network controlling the synthesis of DNA bases as a function of folate metabolism. See Scheme 
1 and its legend as well as the Discussion. CH-FH4-CH: CH-FH4-cyclohydrolase; TS: Thymidilate Synthase.
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hypoxia. Indeed, the occurrence of ESC-like cells in the 
tumor bulk is generally supposed to derive from their 
capacity to home in hypoxic tissue niches, where they can 
survive indefinitely in a dormant state [37]. These cells can 
be generated in the bulk of tumors through the epigenetic 
reprogramming of adult cells triggered and sustained in the 
course of neoplastic progression [13], which indeed consists 
of an uncontrolled drift to DNA mutations called chromatin 
plasticity. Yamanaka and Hochedlinger demonstrated that 
the absence of efficient p53 leads to chromatin instability, 
that strongly facilitates epigenetic reprogramming down to 
ESC [41–45]. Thus, the expression of ETF in the bulk of 
tumors, whatever their origin, represents a powerful drive 
to progression to an anaplastic phenotype. This evolution 
is the main factor determining the risk of relapses, which 
are impossible to prevent by the traditional antineoplastic 
treatments. At the same time, however, the ESC-like cells 
might consent a selective antitumor therapy based on their 
specific vulnerability to pyruvate, FH4 and glutamine, for 
which we here proposed the acronym of CCPF (Cancer- 
Cytotoxic Physiological Factors). According to our 
studies, via a strong reductive shift of NADP/NADPH 
ratio, CCPF impair the aerobic purine synthesis through 
the aerobic utilization of CH2-FH4 in the assembly of the 
10-HCO-FH4 in the purine ring (pathway (1) of Scheme 2). 
The extraordinary advantage of this approach lies in the fact 
that CCPF, being physiological factors, are devoid of any 
general toxicity for human beings.
In the light of all above, the results presented in this 
paper are relevant to cancer therapy. Indeed, LY309887 or 
TDX would be able to kill the bulk of the tumor but not to 
interfere with the ETF-expressing stem cell compartment. 
Furthermore, the use of inhibitors point of pyrimidine 
synthesis, such as TDX, might generate the paradoxical 
effect demonstrated in this paper, namely, the restoration 
within the hypoxic stem cell niches of a more favourable 
equilibrium between the two types of DNA bases, thereby 
favouring the recruitment of dormant cells into the cycling 
state. The low inhibitor concentrations driving this effect 
correspond to the plasmatic levels which are usually 
reached at the end of each treatment cycle and during 
the necessary therapeutic intervals. This may represent a 
serious limit to the use of TS inhibitors On the other hand, 
it is also worth to be taken into consideration the possibility 
that the paradoxical effect of TS inhibitors turn out useful 
to rescue cell sensitivity to anti-proliferative agents if one 
were to adopt a combination therapy protocol.
MATERIALS AND METHODS
Cells and culture conditions
K562 cells were cultured in 24-well dishes 
(EuroClone) at 3 × 104 /ml (2 ml/well) in RPMI 1640 
medium supplemented with 50 units/ml penicillin, 
50 μg/ml streptomycin, and 10% fetal bovine serum (all from 
EuroClone, Paignton, U.K., http://www.euroclone.net/).
Experiments were established with cells rescued 
from maintenance cultures, plated at 5 × 105/ml and 
incubated for 24 hours ("intermediate" passage) at 37°C 
in a water-saturated atmosphere containing 5% CO2 and 
95% air, before the final replating into 24-well dishes. 
Incubation in severe hypoxia was carried out in a water-
saturated atmosphere containing 0.1% O2, 5% CO2, 
95% N2, in a gas-tight incubator/manipulator (Ruskinn 
Concept 400 or Don Whitley Scientific DG250 anaerobic 
workstation) flushed with the above preformed gas 
mixture. Such a workstation allows easy entry and exit of 
materials and sample manipulation without compromising 
the hypoxic environment. Controls of experiments in 
hypoxia have been carried out incubating cells in air, 
which is considered a standard condition for cell culture. 
However, it is worth pointing out that incubation in air 
generates an artificial hyperoxic condition which has 
nothing to do with the real situation occurring in even the 
best-oxygenated tissue environment [46].
Yoshida’s ascites hepatoma AH130 cells were 
maintained and cultured as previously described [3].
Cell viability was assessed by trypan blue exclusion, 
diluting cell suspension 1:1 with a 1% wt/vol trypan blue 
solution (Sigma-Aldrich). The number of total and viable 
cells was counted in a Bürker hemocytometer.
Immunofluorescence
Cell suspension was cytocentrifuged at 800 rpm 
for 15 min and cells processed essentially as previously 
described [3] and assayed with the following antibodies: 
rabbit anti-Nanog, 1:800; mouse anti-Klf4, 1:800; rabbit 
anti-Sox2, 1:800; rabbit anti-Oct3/4, 1:1000 (Stemgent). 
Cells were then incubated with Cy3-conjugated anti-
mouse, or fluorescein-conjugated anti-rabbit secondary 
antibody (Chemicon) at 1:800 dilution. Cell nuclei were 
stained with Hoechst 33258, 1:2000 (Sigma-Aldrich).
HPLC
Organic extracts were obtained from 107 cells with 
75% ultrapure acetonitrile plus 25% 10 mM KH2PO4 at 
pH 7.4. The extracts were completely dehydrated and 
suspended in 20 μl of running buffer and analyzed in 
a Perkin Helmer Series 200, UV/VIS Detector HPLC 
apparatus, as previously described [4].
Flow cytometry
To determine cell cycle distribution, 5 × 105 cells were 
centrifuged for 6 min at 1,200 rpm, resuspended in 500 μl 
of propidium iodide (PI) solution (trisodium citrate 0.1% 
w/v, NP40 0.1% w/v, PI 50 μg/ml) (Merck, Biosciences, 
Calbiochem respectively) and incubated for 30 min at 4°C in 
darkness. Cells were then subjected to flow cytometry (Becton-
Dickinson FACS-Canto) and data analyzed, to determine cell 
cycle distribution, by the Mod fit LT software [3].
Oncotarget11www.impactjournals.com/oncotarget
Drugs and chemicals
Pyruvate, antimycin A, folic acid, purines and 
pyrimidines were purchased from Sigma Aldrich and 
added at the concentration indicated in the legends. 
Antimycin A was dissolved in ethanol.
Raltitrexed (TDX) and LY309887 were kindly 
supplied by Prof. Enrico Mini, Department of Experimental 
and Clinical Medicine, University of Florence, Italy.
Statistical analysis
Significance levels were calculated by the Student’s 
t-test: * = p < 0.05; ** = p < 0.02; *** = p < 0.005.
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